98 related articles for article (PubMed ID: 10088137)
1. Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls.
Sumiyoshi T; Saitoh O; Yotsutsuji T; Itoh H; Kurokawa K; Kurachi M
Neuropsychopharmacology; 1999 Apr; 20(4):365-9. PubMed ID: 10088137
[TBL] [Abstract][Full Text] [Related]
2. Effect of mental stress on plasma homovanillic acid in healthy human subjects.
Sumiyoshi T; Yotsutsuji T; Kurachi M; Itoh H; Kurokawa K; Saitoh O
Neuropsychopharmacology; 1998 Jul; 19(1):70-3. PubMed ID: 9608578
[TBL] [Abstract][Full Text] [Related]
3. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
[TBL] [Abstract][Full Text] [Related]
4. Plasma homovanillic acid in the prodromal phase of schizophrenia.
Sumiyoshi T; Kurachi M; Kurokawa K; Yotsutsuji T; Uehara T; Itoh H; Saitoh O
Biol Psychiatry; 2000 Mar; 47(5):428-33. PubMed ID: 10704954
[TBL] [Abstract][Full Text] [Related]
5. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Sumiyoshi T; Hasegawa M; Jayathilake K; Meltzer HY
Biol Psychiatry; 1997 Mar; 41(5):560-6. PubMed ID: 9046988
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
Koreen AR; Lieberman J; Alvir J; Mayerhoff D; Loebel A; Chakos M; Amin F; Cooper T
Arch Gen Psychiatry; 1994 Feb; 51(2):132-8. PubMed ID: 7905259
[TBL] [Abstract][Full Text] [Related]
7. Plasma HVA in psychiatric patients: longitudinal studies.
Javaid JI; Sharma RP; Janicak PG; Davis JM
Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
[TBL] [Abstract][Full Text] [Related]
8. Lack of effect of laboratory-provoked anxiety on plasma homovanillic acid concentration in normal subjects.
Zemishlany Z; Davidson M
Biol Psychiatry; 1996 Aug; 40(4):247-52. PubMed ID: 8871770
[TBL] [Abstract][Full Text] [Related]
9. Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Dávila R; Zumárraga M; Basterreche N; Arrúe A; Anguiano JB
Psychiatry Res; 2007 May; 151(1-2):163-8. PubMed ID: 17434602
[TBL] [Abstract][Full Text] [Related]
10. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
11. Measurement of plasma homovanillic acid concentrations in schizophrenic patients.
Kaminski R; Powchick P; Warne PA; Goldstein M; McQueeney RT; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(3):271-87. PubMed ID: 2193315
[TBL] [Abstract][Full Text] [Related]
12. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Chen TY; Lee CF; Lung FW; Lee TC; Lin WL; Hu WH; Yeh EK; Chang WH
Taiwan Yi Xue Hui Za Zhi; 1989 Jun; 88(6):584-8. PubMed ID: 2571672
[TBL] [Abstract][Full Text] [Related]
13. Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Zhang ZJ; Reynolds GP; Ramchand C; Peet M; Shah S
Acta Pharmacol Sin; 2001 Jan; 22(1):76-80. PubMed ID: 11730567
[TBL] [Abstract][Full Text] [Related]
14. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
15. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Khan RS; Amin F; Powchik P; Knott P; Goldstein M; Apter S; Kerman B; Jaff S; Davidson M
Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(6):879-84. PubMed ID: 1980541
[TBL] [Abstract][Full Text] [Related]
16. Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
Zumárraga M; Dávila R; González-Torres MA; Anguiano JB; Zabalo MJ; Basterreche N; Arrúe A; Zamalloa MI; Guimón J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):713-9. PubMed ID: 17291661
[TBL] [Abstract][Full Text] [Related]
17. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.
Sumiyoshi T; Roy A; Kim CH; Jayathilake K; Lee MA; Sumiyoshi C; Meltzer HY
Psychopharmacology (Berl); 2004 Dec; 177(1-2):79-83. PubMed ID: 15179543
[TBL] [Abstract][Full Text] [Related]
18. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Arrúe A; Dávila R; Zumárraga M; Basterreche N; González-Torres MA; Goienetxea B; Zamalloa MI; Anguiano JB; Guimón J
Neurochem Res; 2010 Feb; 35(2):247-53. PubMed ID: 19701707
[TBL] [Abstract][Full Text] [Related]
19. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
[TBL] [Abstract][Full Text] [Related]
20. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia.
Davidson M; Kahn RS; Stern RG; Hirschowitz J; Apter S; Knott P; Davis KL
Psychiatry Res; 1993 Feb; 46(2):151-63. PubMed ID: 8483974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
